New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 10.89mg equivalent to lisinopril 10 mg;  ;  ;   - tablet - 10 mg - active: lisinopril dihydrate 10.89mg equivalent to lisinopril 10 mg       excipient: calcium hydrogen phosphate dihydrate ferric oxide red (ci77491) magnesium stearate maize starch mannitol - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 2.723mg equivalent to lisinopril 2.5 mg;  ;  ;   - tablet - 2.5 mg - active: lisinopril dihydrate 2.723mg equivalent to lisinopril 2.5 mg       excipient: calcium hydrogen phosphate dihydrate magnesium stearate maize starch mannitol - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 21.78mg equivalent to lisinopril 20 mg;  ;  ;   - tablet - 20 mg - active: lisinopril dihydrate 21.78mg equivalent to lisinopril 20 mg       excipient: calcium hydrogen phosphate dihydrate ferric oxide red (ci77491) magnesium stearate maize starch mannitol - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 5.445mg equivalent to lisinopril 5 mg;  ;  ;   - tablet - 5 mg - active: lisinopril dihydrate 5.445mg equivalent to lisinopril 5 mg       excipient: calcium hydrogen phosphate dihydrate ferric oxide red (ci77491) magnesium stearate maize starch mannitol - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

Ireland - English - HPRA (Health Products Regulatory Authority)

as grindeks - lisinopril dihydrate - tablet - lisinopril

Ireland - English - HPRA (Health Products Regulatory Authority)

as grindeks - lisinopril dihydrate - tablet - lisinopril

Ireland - English - HPRA (Health Products Regulatory Authority)

as grindeks - lisinopril dihydrate - tablet - lisinopril

Ireland - English - HPRA (Health Products Regulatory Authority)

essential pharmaceuticals limited - lisinopril dihydrate - oral solution - 1 mg/ml - lisinopril - angiotensin-converting enzyme inhibitors - treatment of hypertension; treatment of symptomatic heart failure; treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction; treatment of renal disease in hypertensive patients with type 2 diabetes mellitus and incipient nephropathy

United States - English - NLM (National Library of Medicine)

stat rx usa llc - lisinopril (unii: e7199s1ywr) (lisinopril anhydrous - unii:7q3p4bs2fd) - lisinopril 20 mg - lisinopril tablet is indicated for the treatment of hypertension. it may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. lisinopril tablet is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. lisinopril tablet is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers. in using lisinopril tablet, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril tablet does not have a similar risk (see warnings). in considering the use of lisinopril tablet, it should

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - lisinopril - oral tablet - 5mg